Asset Details
Do you wish to reserve the book?
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Do you wish to request the book?
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
2011
Overview
In this trial, teriflunomide reduced annualized relapse rates and disability progression over 108 weeks of treatment in patients with relapsing MS, although diarrhea, nausea, hair thinning, and abnormalities in alanine aminotransferase levels were reported.
Teriflunomide, the active metabolite of leflunomide, is being investigated as a new oral disease-modifying therapy for relapsing forms of multiple sclerosis.
1
Although the two drugs are related in structure, teriflunomide has a distinct profile.
2
It reversibly inhibits dihydroorotate dehydrogenase, a key mitochondrial enzyme involved in new pyrimidine synthesis for DNA replication. Consequently, the drug reduces T- and B-cell activation, proliferation, and function in response to autoantigens. However, teriflunomide preserves the replication and function of slowly dividing cells that use exogenous supplies of pyrimidine nucleotides through the so-called salvage pathway.
3
–
5
Teriflunomide has been shown to delay the onset of disease, . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Alanine
/ Alanine Transaminase - blood
/ Biological and medical sciences
/ Crotonates - adverse effects
/ Crotonates - therapeutic use
/ Diarrhea
/ Disease
/ Enzyme Inhibitors - adverse effects
/ Enzyme Inhibitors - therapeutic use
/ Female
/ Humans
/ Male
/ Multiple Sclerosis, Relapsing-Remitting - drug therapy
/ Multiple Sclerosis, Relapsing-Remitting - pathology
/ Nausea
/ NMR
/ Oxidoreductases Acting on CH-CH Group Donors - antagonists & inhibitors
/ Toluidines - adverse effects
